{"id":"alx-0061","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4297692","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By binding to both IL-17A and IL-17F, ALX-0061 inhibits their interaction with the IL-17 receptor, reducing inflammation and the associated symptoms in autoimmune conditions.","oneSentence":"ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:08:34.082Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT02309359","phase":"PHASE2","title":"A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-01","conditions":"Rheumatoid Arthritis","enrollment":345},{"nctId":"NCT02287922","phase":"PHASE2","title":"A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02518620","phase":"PHASE2","title":"An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-07","conditions":"Rheumatoid Arthritis","enrollment":406},{"nctId":"NCT02437890","phase":"PHASE2","title":"A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-07","conditions":"Lupus Erythematosus, Systemic","enrollment":312},{"nctId":"NCT01284569","phase":"PHASE1, PHASE2","title":"Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":65},{"nctId":"NCT02101073","phase":"PHASE1","title":"ALX-0061 Phase I Bioavailability Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2014-03-31","conditions":"Rheumatoid Arthritis","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vobarilizumab"],"phase":"phase_2","status":"active","brandName":"ALX-0061","genericName":"ALX-0061","companyName":"Ablynx, a Sanofi company","companyId":"ablynx-a-sanofi-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"ALX-0061 is a nanobody targeting IL-17A and IL-17F, which are pro-inflammatory cytokines involved in autoimmune diseases. Used for Psoriasis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}